New nonchemotherapy treatment options for cutaneous T-cell lymphomas

被引:5
作者
Xu, Suzanne [1 ]
Foss, Francine [2 ]
机构
[1] Yale Univ, Sch Med, New Haven, CT USA
[2] Yale Univ, Sch Med, Hematol & Stem Cell Transplantat, New Haven, CT 06510 USA
关键词
Cutaneous T cell lymphoma; mycosis fungoides; Sezary syndrome; mogamulizumab; brentuximab vedotin; immunotherapy; photopheresis; HISTONE DEACETYLASE INHIBITORS; PHASE-II TRIAL; MYCOSIS-FUNGOIDES; SEZARY-SYNDROME; BRENTUXIMAB VEDOTIN; ORAL BEXAROTENE; EXTRACORPOREAL PHOTOCHEMOTHERAPY; MONOCLONAL-ANTIBODY; DENILEUKIN DIFTITOX; RESPONSE CRITERIA;
D O I
10.1080/14737140.2021.1882859
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction The most common types of CTCL are mycosis fungoides (MF) and Sezary syndrome (SS). In both MF and SS, complete responses to treatment are uncommon. Recent developments and understanding of the biology of MF/SS have led to novel agents which may offer prolonged responses with less toxicity compared to conventional chemotherapy approaches. Areas Covered In this review, we discuss the efficacy and safety of new nonchemotherapy treatment options including antibody agents, small molecule inhibitors, fusion proteins, and CAR T-cell therapy. We also reflect on older immunomodulatory treatments including retinoids and histone deacetylase inhibitors. Expert Opinion Patients with MF/SS who require systemic therapy often progress through multiple agents sequentially, thus the need for additional novel agents in the treatment armamentarium. Antibody-based therapies such as alemtuzumab are highly effective in the blood compartment of disease, while brentuximab vedotin has shown higher activity in skin and lymph nodes. Checkpoint inhibitors may play a role in treating MF/SS but may induce hyperprogression, and engineered T cells and bispecific antibodies recruiting immune effectors are being developed and may show promise in the future.
引用
收藏
页码:1017 / 1027
页数:11
相关论文
共 104 条
[1]  
[Anonymous], 2024, KYMRIAH. (Tisagenlecleucel)
[2]   A Phase 1 Study of Nivolumab in Combination with Ipilimumab for Relapsed or Refractory Hematologic Malignancies (CheckMate 039) [J].
Ansell, Stephen ;
Gutierrez, Martin E. ;
Shipp, Margaret A. ;
Gladstone, Douglas ;
Moskowitz, Alison ;
Borello, Ivan ;
Popa-Mckiver, Mihaela ;
Farsaci, Benedetto ;
Zhu, Lili ;
Lesokhin, Alexander M. ;
Armand, Philippe .
BLOOD, 2016, 128 (22)
[3]   Allogeneic hematopoietic stem cell transplantation for refractory mycosis fungoides (MF) and Sezary syndrome (SS) [J].
Atilla, Erden ;
Atilla, Pinar Ataca ;
Bozdag, Sinem Civriz ;
Yuksel, Meltem Kurt ;
Toprak, Selami Kocak ;
Topcuoglu, Pervin ;
Akay, Bengu Nisa ;
Sanli, Hatice ;
Gurman, Gunhan ;
Ozcan, Muhit .
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2017, 106 (03) :426-430
[4]   CD4+ cutaneous T-cell lymphoma cells express the p140-killer cell immunoglobulin-like receptor [J].
Bagot, M ;
Moretta, A ;
Sivori, S ;
Biassoni, R ;
Cantoni, C ;
Bottino, C ;
Boumsell, L ;
Bensussan, A .
BLOOD, 2001, 97 (05) :1388-1391
[5]   IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial [J].
Bagot, Martine ;
Porcu, Pierluigi ;
Marie-Cardine, Anne ;
Battistella, Maxime ;
William, Basem M. ;
Vermeer, Maarten ;
Whittaker, Sean ;
Rotolo, Federico ;
Ram-Wolff, Caroline ;
Khodadoust, Michael S. ;
Bensussan, Armand ;
Paturel, Carine ;
Bonnafous, Cecile ;
Sicard, Helene ;
Azim, Hatem A., Jr. ;
Kim, Youn H. .
LANCET ONCOLOGY, 2019, 20 (08) :1160-1170
[6]   IPH4102; An Anti-KIR3DL2 Monoclonal Antibody in Refractory Sezary Syndrome: Results from a Multicenter Phase 1 Trial [J].
Bagot, Martine ;
Porcu, Pierluigi ;
William, Basem M. ;
Battistella, Maxime ;
Vermeer, Maarten ;
Whittaker, Sean ;
Ram-Wolff, Caroline ;
Khodadoust, Michael S. ;
Sicard, Helene ;
Azim, Hatem A., Jr. ;
Kim, Youn H. .
BLOOD, 2018, 132
[7]   Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative data [J].
Bates, Susan E. ;
Eisch, Robin ;
Ling, Alexander ;
Rosing, Douglas ;
Turner, Maria ;
Pittaluga, Stefania ;
Prince, H. Miles ;
Kirschbaum, Mark H. ;
Allen, Steven L. ;
Zain, Jasmine ;
Geskin, Larisa J. ;
Joske, David ;
Popplewell, Leslie ;
Cowen, Edward W. ;
Jaffe, Elaine S. ;
Nichols, Jean ;
Kennedy, Sally ;
Steinberg, Seth M. ;
Liewehr, David J. ;
Showe, Louise C. ;
Steakley, Caryn ;
Wright, John ;
Fojo, Tito ;
Litman, Thomas ;
Piekarz, Richard L. .
BRITISH JOURNAL OF HAEMATOLOGY, 2015, 170 (01) :96-109
[8]   Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance [J].
Boyiadzis, Michael M. ;
Dhodapkar, Madhav V. ;
Brentjens, Renier J. ;
Kochenderfer, James N. ;
Neelapu, Sattva S. ;
Maus, Marcela V. ;
Porter, David L. ;
Maloney, David G. ;
Grupp, Stephan A. ;
Mackall, Crystal L. ;
June, Carl H. ;
Bishop, Michael R. .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
[9]   Brentuximab vedotin: An anti-CD30 antibody-drug conjugate [J].
Bradley, Amber M. ;
Devine, Meghan ;
DeRemer, David .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2013, 70 (07) :589-597
[10]   Vorinostat-An Overview [J].
Bubna, Aditya Kumar .
INDIAN JOURNAL OF DERMATOLOGY, 2015, 60 (04) :419